129 related articles for article (PubMed ID: 38295333)
1. Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation.
Takahashi S; Minnie SA; Ensbey KS; Schmidt CR; Sekiguchi T; Legg SRW; Zhang P; Koyama M; Olver SD; Collinge AD; Keshmiri S; Comstock ML; Varelias A; Green DJ; Hill GR
Blood; 2024 Apr; 143(16):1656-1669. PubMed ID: 38295333
[TBL] [Abstract][Full Text] [Related]
2. Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.
Derman BA; Zha Y; Zimmerman TM; Malloy R; Jakubowiak A; Bishop MR; Kline J
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940591
[TBL] [Abstract][Full Text] [Related]
3. TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice.
Minnie SA; Waltner OG; Ensbey KS; Olver SD; Collinge AD; Sester DP; Schmidt CR; Legg SR; Takahashi S; Nemychenkov NS; Sekiguchi T; Driessens G; Zhang P; Koyama M; Spencer A; Holmberg LA; Furlan SN; Varelias A; Hill GR
J Clin Invest; 2023 Feb; 133(4):. PubMed ID: 36512425
[TBL] [Abstract][Full Text] [Related]
4. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor.
Condomines M; Quittet P; Lu ZY; Nadal L; Latry P; Lopez E; Baudard M; Requirand G; Duperray C; Schved JF; Rossi JF; Tarte K; Klein B
J Immunol; 2006 Jun; 176(11):6631-9. PubMed ID: 16709821
[TBL] [Abstract][Full Text] [Related]
5. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens.
Oyekunle A; Shumilov E; Kostrewa P; Burchert A; Trümper L; Wuchter P; Wulf G; Bacher U; Kröger N
Biol Blood Marrow Transplant; 2018 Feb; 24(2):276-281. PubMed ID: 29037891
[TBL] [Abstract][Full Text] [Related]
7. Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.
Parrish C; Morris CTCM; Williams CD; Cairns DA; Cavenagh J; Snowden JA; Ashcroft J; Cavet J; Hunter H; Bird JM; Chalmers A; Brown JM; Yong K; Schey S; Chown S; Cook G;
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1009-1016. PubMed ID: 26827659
[TBL] [Abstract][Full Text] [Related]
8. Meloxicam with Filgrastim may Reduce Oxidative Stress in Hematopoietic Progenitor Cells during Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma.
Patterson AM; Zhang S; Liu L; Li H; Singh P; Liu Y; Farag SS; Pelus LM
Stem Cell Rev Rep; 2021 Dec; 17(6):2124-2138. PubMed ID: 34510361
[TBL] [Abstract][Full Text] [Related]
9. Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma.
Lee L; Alrasheed N; Khandelwal G; Fitzsimons E; Richards H; Wilson W; Chavda SJ; Henry J; Conde L; De Massy MR; Chin M; Galas-Filipowicz D; Herrero J; Chain B; Quezada SA; Yong K
Front Immunol; 2021; 12():618610. PubMed ID: 33717112
[TBL] [Abstract][Full Text] [Related]
10. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
Chhabra S; Callander N; Watts NL; Costa LJ; Thapa B; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Anderson LD; Bal S; Dhakal B; Nathwani N; Shah N; Medvedova E; Bumma N; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Schmidt T; Orlowski RZ; Shain KH; Cowan AJ; Dholaria B; Cornell RF; Jerkins JH; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG; Voorhees PM
Transplant Cell Ther; 2023 Mar; 29(3):174.e1-174.e10. PubMed ID: 36494017
[TBL] [Abstract][Full Text] [Related]
11. T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy.
Chung DJ; Pronschinske KB; Shyer JA; Sharma S; Leung S; Curran SA; Lesokhin AM; Devlin SM; Giralt SA; Young JW
Cancer Immunol Res; 2016 Jan; 4(1):61-71. PubMed ID: 26464015
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of VRD regimen of autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma].
Yan S; Jin S; Wang PF; Yan LZ; Shang JJ; Shi XL; Wu XJ; Zhai YY; Yao WQ; Wang J; Yao Y; Fu CC
Zhonghua Nei Ke Za Zhi; 2023 Jul; 62(7):819-825. PubMed ID: 37394852
[No Abstract] [Full Text] [Related]
13. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Tuchman SA; Bacon WA; Huang LW; Long G; Rizzieri D; Horwitz M; Chute JP; Sullivan K; Morris Engemann A; Yopp A; Li Z; Corbet K; Chao N; Gasparetto C
J Clin Apher; 2015 Jun; 30(3):176-82. PubMed ID: 25293363
[TBL] [Abstract][Full Text] [Related]
15. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
16. Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
Minnie SA; Hill GR
Front Immunol; 2021; 12():651288. PubMed ID: 33777050
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
Garfall AL; Stadtmauer EA; Hwang WT; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV; Dhodapkar K; Das R; Vogl DT; Weiss BM; Cohen AD; Mangan PA; Ayers EC; Nunez-Cruz S; Kulikovskaya I; Davis MM; Lamontagne A; Dengel K; Kerr ND; Young RM; Siegel DL; Levine BL; Milone MC; Maus MV; June CH
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669947
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis.
Clave E; Douay C; Coman T; Busson M; Bompoint C; Moins-Teisserenc H; Glauzy S; Carmagnat M; Gorin NC; Toubert A; Garderet L
Leuk Lymphoma; 2014 Aug; 55(8):1788-95. PubMed ID: 24237448
[TBL] [Abstract][Full Text] [Related]
19. Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma.
Damron EP; Qazilbash MH; Fang PQ; Wu SY; Dabaja BS; Rondon G; Hosing C; Champlin RE; Bashir Q; Shpall EJ; Knafl MK; Lee HC; Manasanch EE; Patel K; Thomas SK; Orlowski RZ; Weber DM; Pinnix CC; Gunther JR
Transplant Cell Ther; 2023 Jan; 29(1):37.e1-37.e7. PubMed ID: 37753818
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma.
Keruakous AR; Asch A; Aljumaily R; Zhao D; Yuen C
Transpl Immunol; 2022 Apr; 71():101544. PubMed ID: 35093506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
